Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Tarsus Pharmaceuticals, Inc.

Market Cap 2.69B 2.34B 2.15B 2.02B 3.77B 258B 3.85B 25.7B 9.95B 124B 10.11B 9.89B 432B P/E Ratio 2026 *
-97.8x
P/E Ratio 2027 * 20.1x
Enterprise Value 2.69B 2.34B 2.15B 2.02B 3.77B 258B 3.85B 25.7B 9.95B 124B 10.11B 9.89B 432B EV / Sales 2026 *
3.87x
EV / Sales 2027 * 2.98x
Free-Float
96.93%
Yield 2026 *
-
Yield 2027 * -
1 day+2.19%
1 week+3.76%
Current month+5.40%
1 month+4.96%
3 months-10.40%
6 months-23.37%
Current year-23.53%
1 week 58.49
Extreme 58.49
64.59
1 month 56
Extreme 56
65.99
Current year 56
Extreme 56
83.92
1 year 38.51
Extreme 38.51
85.25
3 years 12.57
Extreme 12.57
85.25
5 years 10.8
Extreme 10.8001
85.25
10 years 10.8
Extreme 10.8001
85.25
Manager TitleAgeSince
Chief Executive Officer 48 2018-08-31
Director of Finance/CFO 64 2023-04-23
Chief Tech/Sci/R&D Officer - 2022-07-31
Director TitleAgeSince
Chairman 48 2022-12-01
Director/Board Member 71 2019-11-30
Director/Board Member 80 2016-12-31
Date Insider Type Main position Quantity % Market Cap.
04-23Fiscal year

Director

2,766 0.0065%
03-19Sell

Chief Operating Officer

2,989 0.0070%
03-16Sell

General Counsel

12,440 0.0292%
Change 5-day change 1-year change 3-year change Capi.($)
+2.19%+3.76%+52.86%+247.06% 2.69B
+1.63%-2.74%+17.91%-18.09% 62.21B
+0.70%+4.60%+66.92%+221.25% 59.45B
-0.92%+28.60%+28.60%+28.60% 38.9B
+0.26%+9.80%-55.40%-65.15% 36.4B
+2.94%+1.79%+50.28%-35.26% 29.52B
+2.32%+6.51%+56.62%+76.65% 21.54B
+7.94%-3.78%+78.88%-59.73% 19.7B
+4.80%-0.20%-5.33%+112.95% 16.18B
-0.91%-2.78%+48.09%+99.17% 15.89B
Average +2.10%+1.69%+33.94%+60.75% 30.25B
Weighted average by Cap. +1.59%+1.89%+30.63%+47.18%

Financials

2026 *2027 *
Net sales 696M 604M 557M 522M 975M 66.68B 996M 6.64B 2.57B 32.14B 2.61B 2.56B 112B 905M 785M 724M 678M 1.27B 86.61B 1.29B 8.63B 3.34B 41.75B 3.4B 3.32B 145B
Net income -28.48M -24.71M -22.78M -21.34M -39.88M -2.73B -40.71M -272M -105M -1.31B -107M -105M -4.57B 158M 137M 126M 118M 221M 15.12B 226M 1.51B 583M 7.29B 593M 580M 25.35B
Net Debt - -
Logo Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.
Employees
370
Date Price Change Volume
26-06-11 62.61 $ +2.19% 399,703
26-06-10 61.27 $ -0.45% 319,938
26-06-09 61.55 $ +3.20% 615,565
26-06-08 59.64 $ +0.61% 443,379
26-06-05 59.28 $ -1.76% 370,112
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
62.61USD
Average target price
94.11USD
Spread / Average Target
+50.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TARS Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!